1479-0008
Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic nonsquamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06151574?term=1479-0008&rank=1
Practices offering this clinical trial:
20200041
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Cancer Types: Lung CancerLines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06211036?term=20200041&rank=1
Practices offering this clinical trial:
20210031
A Randomized, Double-blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with Opdivo (Nivolumab) in Subjects with Treatment-naïve Unrespectable or Metastatic Melanoma
Cancer Types: MelanomaLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05939219?term=20210031&rank=1
Practices offering this clinical trial:
61186372NS2012 COPERNICUS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT06667076?term=61186372NSC2012&rank=1
Practices offering this clinical trial:
61186372NSC2007
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06120140?term=61186372nsc2007&rank=1
Practices offering this clinical trial:
BGB-3111-308
A Phase 3, Open-Label Study of Zanubrutinib Plus Anti-CD20 Versus Rituximab and Lenalidomide (R2) in Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Cancer Types: LymphomaLines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05100862?cond=Follicular%20Lymphoma&term=BGB-3111-308&rank=1
Practices offering this clinical trial:
J3M-MC-JZQB SUNRAY-01
A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06119581?term=j3m-mc-jzqb&rank=1
Practices offering this clinical trial:
PUMA-ALI-1201
A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER
Cancer Types: Breast CancerLines of Therapy: 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT06369285?term=puma-ali-1201&rank=1
Practices offering this clinical trial:
TP-CA-002
TEMPUS GEMINI NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)
Cancer Types: Lung CancerLines of Therapy: Neo-Adjuvant, 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05236114?term=TP-CA-002&rank=1
Practices offering this clinical trial:
TP-CA-006 PHOENIX
Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)
Cancer Types: Head and Neck Cancer, Supportive CareLines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06163534?term=tp-ca-006&rank=1
Practices offering this clinical trial:
TP-CA-007
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Cancer Types: Colon and Rectal Cancer, Lung Cancer, Pancreatic CancerLines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06207032?term=tp-ca-007&rank=1
Practices offering this clinical trial: